Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Iambic Therapeutics, OpenAI, and 370+ companies. 5-min read every Tuesday.
Iambic Therapeutics uses AI-assisted drug discovery combining molecular simulation, high-throughput virtual screening, and experimental validation to identify novel therapeutics for challenging diseases. Valued at $500M with $150M raised, Iambic has multiple discovery programs in oncology and rare diseases. Major AI biotech IPO candidate as AI-driven small molecule drug discovery accelerates through clinical validation and partnership deals with major pharma.
| Industry | Biotechnology |
| Stage | Series C |
| IPO Status | Private |
| Valuation | $1.2B |
| Total Funding | $263M |
| Headquarters | San Diego, CA |
OpenAI is valued at $920B — the world's most valuable AI company, backed by over $65B in funding. The company recently restructured as a Public Benefit Corporation to support its mission of developing safe AGI.
| Industry | Artificial Intelligence |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $920.0B |
| Total Funding | $65.4B |
| Headquarters | San Francisco, CA |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Iambic Therapeutics is valued at $1.2B. OpenAI is valued at $920.0B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Iambic Therapeutics has raised $263M. OpenAI has raised $65.4B.
Iambic Therapeutics is currently private. OpenAI is currently private. Track both on TechStackIPO for S-1 filings and IPO announcements.
Iambic Therapeutics operates in Biotechnology, while OpenAI operates in Artificial Intelligence.
Iambic Therapeutics is a Biotechnology company valued at $1.2B with $263M raised. OpenAI is a Artificial Intelligence company valued at $920.0B with $65.4B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Iambic Therapeutics and OpenAI through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.